A5000869254- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- Transplantation: Methods and Outcomes
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Family Support in Illness
- Systemic Sclerosis and Related Diseases
- Parkinson's Disease and Spinal Disorders
- Childhood Cancer Survivors' Quality of Life
- Myasthenia Gravis and Thymoma
- CAR-T cell therapy research
- Renal Transplantation Outcomes and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Reproductive Biology and Fertility
- Hemoglobinopathies and Related Disorders
- Mast cells and histamine
- Click Chemistry and Applications
- Multiple Myeloma Research and Treatments
- Family and Disability Support Research
- Viral-associated cancers and disorders
University of Calgary
2016-2025
Alberta Health Services
2013-2025
Medical College of Wisconsin
2021
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2019
Fred Hutch Cancer Center
2017-2019
Cancer Research Center
2019
A cute graft-versus-host disease remains a major threat to successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances resulted improved specifically among those diagnosed with acute disease. We examined following diagnosis of grade II-IV according time period, explored effects original prophylaxis regimen maximum overall Between 1999 2012, 2,905 patients myeloid leukemia...
Graft-versus-host disease (GVHD) is a major transplantation complication. The purpose of this study was to measure immune cell subsets by flow cytometry early after (before median day GVHD onset) identify that may play role in pathogenesis. We also measured the later determine which be influenced or its treatment. studied 219 patients. found acute (aGVHD) preceded high counts CD4 T cells and CD8 cells. It followed low total naive B cells, cytolytic NK myeloid plasmacytoid dendritic Chronic...
Caregivers are critical to recipient recovery after hematopoietic cell transplant (HCT); however, little is known about their long-term health and quality of life (QoL). In this study we surveyed 4446 caregiver–recipient pairs in the post-HCT period describe QoL its determinants. total, 849 at a median 6 years autologous or allogeneic HCT responded. Among responding caregivers post-HCT, 67% were women 68% indicated they still providing care recipient. Mean measures above general population...
Azithromycin exposure during the early phase of allogeneic hematopoietic cell transplantation (HCT) has been associated with an increased incidence hematologic relapse. We assessed impact azithromycin on occurrence relapse or new subsequent neoplasm (SN) in patients bronchiolitis obliterans syndrome (BOS) after HCT who are commonly treated alone combination other agents. In a retrospective study BOS from 2 large allograft centers, effect risk SN was estimated Cox model time-dependent...
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (allo-HCT) is often diagnosed at a late stage when lung dysfunction severe and irreversible. Identifying patients early may offer improved strategies for detection that could avert the morbidity mortality of BOS. This study aimed to determine whether decline in function before (days +80 +100) allo-HCT are associated with risk BOS beyond 6 months post-transplantation. In single-center cohort 2941...
Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return work post-HCT. Work-related outcomes in this population remain understudied, however. We conducted study assess post-HCT status HCT who underwent as YAs and analyze patient-, disease-, HCT-related factors associated with their 1 year Using Center International Blood Marrow Transplant Research data, we evaluated (full-time, part-time...
Post-transplant lymphoproliferative disorder (PTLD) is a potentially serious complication that occurs following hematopoietic cell transplantation (HCT), in which B cells transformed by Epstein-Barr virus (EBV) proliferate uncontrollably. It unknown whether risk factors for the incidence of PTLD are identical to those mortality due PTLD, clinically more important outcome. We sought determine influencing and cohort 1184 allogenic HCT recipients. All patients were predisposed because their...
Summary Although autologous stem cell transplantation (ASCT) can achieve durable responses in eligible patients with follicular lymphoma (FL), long‐term follow‐up is needed to determine if it has curative potential. This retrospective, multicenter study included 162 who received ASCT for relapsed FL Alberta, Canada. With a median (range) time of 12.5 years (0.1–27.9), the 12‐year time‐to‐progression (TTP) was 57% (95% confidence interval [CI] 49%–65%), time‐to‐next‐treatment 61% CI 52%–69%),...
Antithymocyte globulin (ATG) levels and clearance vary significantly among patients receiving the same weight-based dose of ATG. To date, ATG area under curve (AUC), its determinants, impact on clinical outcomes have been examined in pediatric hematopoietic cell transplant (HCT) adult nonmyeloablative HCT. Here we set out to examine AUC 219 uniformly treated adults undergoing myeloablative allogeneic HCT at our institution. Sera were collected for determination pre- or post-HCT AUC. The...
Abstract Patient-reported outcomes (PROs) capture subjective social determinants of health (SDOHs), which can affect through the stress response pathway. The conserved transcriptional to adversity (CTRA) is a stress-mediated proinflammatory transcriptomic pattern that has been linked adverse hematopoietic cell transplant (HCT) outcomes. This study examined association pretransplant CTRA with patient-reported SDOHs in allogeneic HCT recipients. In this cross-sectional study, pre-HCT...
This is a consensus-based Canadian guideline whose primary purpose to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across country. Creating uniform healthcare guidance in Canada challenge for number reasons including differences authority structure, funding access resources between provinces territories, as well geographic size. These can lead variable unequal effective therapies GvHD. document will provide comprehensive practical that be applied by...
Abstract It remains unknown why rabbit antithymocyte globulin (ATG; Thymoglobulin) has not affected relapse after hematopoietic cell transplantation (HCT) in randomized studies. We hypothesized that high pre-HCT ATG area under the curve (AUC) would be associated with a low incidence of relapse, whereas post-HCT AUC relapse. measured serum levels capable binding to mononuclear cells (MNCs), lymphocytes, T cells, CD4 or CD33 cells. estimated pre- and AUCs 152 adult recipients myeloablative...
Up to 25% of patients with myasthenia gravis (MG) have refractory disease despite trials multiple immunosuppressants. Several case series describe acetylcholine receptor antibody-positive (AChR) MG treated autologous hematopoietic stem cell transplant (HSCT). In this report, we three anti-muscle-specific kinase (MuSK) HSCT.We included all who had undergone HSCT anti-MuSK identified through the records Alberta Blood and Marrow Transplant Program. We collected demographic clinical data...
Optimal conditioning and graft-vs-host disease (GVHD) prophylaxis for hematopoietic cell transplantation (HCT) are unknown. Here, we report on outcomes after low toxicity, myeloablative consisting of fludarabine, busulfan, 4 Gy total body irradiation, in combination with thymoglobulin post-transplant methotrexate cyclosporine. We retrospectively studied 700 patients hematologic malignancies who received blood stem cells from 7 to 8/8 HLA-matched unrelated or related donors. Median follow-up...